The DOI matches its Crossref record; 133 of the 135 references it cites were found in a registry or an index.
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
Abstract
Background Conventional meta-analyses have shown inconsistent results for efficacy of second-generation antidepressants. We therefore did a multiple-treatments meta-analysis, which accounts for both direct and indirect comparisons, to assess the effects of 12 new-generation antidepressants on major depression. Methods We systematically reviewed 117 randomised controlled trials (25 928 participants) from 1991 up to Nov 30, 2007, which compared any of the following antidepressants at therapeutic dose range for the acute treatment of unipolar major depression in adults: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine. The main outcomes were the proportion of patients who responded to or dropped out of the allocated treatment. Analysis was done on an intention-to-treat basis. Findings Mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than duloxetine (odds ratios [OR] 1.39, 1.33, 1.30 and 1.27, respectively), fluoxetine (1.37, 1.32, 1.28, and 1.25, respectively), fluvoxamine (1.41, 1.35, 1.30, and 1.27, respectively), paroxetine (1.35, 1.30, 1.27, and 1.22, respectively), and reboxetine (2.03, 1.95, 1.89, and 1.85, respectively). Reboxetine was significantly less efficacious than all the other antidepressants tested. Escitalopram and sertraline showed the best profile of acceptability, leading to significantly fewer discontinuations than…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All-cause discontinuation was used as a measure for the acceptability of treatments, because it encompasses efficacy and tolerability.9”
In the citing paper
“We also found that the efficacy of antidepressants for BD requires more evidence [68–70].”
From Bright light therapy in the treatment of patients with bipolar disorder: A systematic review and meta-analysis (2020) · cites this paper as [70]
In the citing paper
“Currently approved treatments for major depressive disorder (MDD), including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), effectively reduce MDD symptoms (Arroll et al., 2005;Cipriani et al., 2009).”
In the citing paper
“Because asymptomatic participants in a large prospective prevention trial might be exposed to an experimental compound for many years, the compound should have a proven safety record, as is the case for selective serotonin reuptake inhibitor (SSRI) drugs.”
From An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) · cites this paper as [17]
In the citing paper
“Citalopram is one of the most selective SSRIs for serotonin re-uptake and has among the most favorable side effect profiles compared with other antidepressants (17).”
From An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice (2014) · cites this paper as [17]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Self-citationMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816
Sterne, J. A. C. (2001) · BMJ · doi:10.1136/bmj.322.7280.226 · Cited by 1,466
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Evaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Self-citationA systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Smith, D., Dempster, C., Glanville, J., Freemantle, N., & Anderson, I. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.396 · Cited by 538
Research works printed but not linked: 7
- Akkaya, 2003, Comparison of venlafaxine XR and reboxetine in terms of efficacy and safety in major depressive disorder, Yeni Symposium, 41, 170
- Gagiano, 1993, A double blind comparison of paroxetine and fluoxetine in patients with major depression, Br J Clin Res, 4, 145
- McPartlin, 1998, A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice, Prim Care Psychiatry, 4, 127
- Ontiveros, 1997, A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression, Br J Clin Res, 8, 23
- Schoemaker, 2002, First, randomized, double-blind comparison of mirtazapine (15–45 mg) and fluvoxamine (50–150 mg) in the treatment of depression, Int J Neuropsychopharmacol, 5, 140
- Tylee, 1997, A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general-practice, Prim Care Psychiatry, 3, 51
- Yang, 2003, Milnacipran versus sertraline in major depressive disorder: a double-blind randomized comparative study on the treatment effect and beta-adrenergic receptor responsiveness, Korean J Psychopharmacol, 14, 387
Cited by
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Sekhon, M., Cartwright, M., & Francis, J. J. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-2031-8 · Cited by 3,938
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Self-citationCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Self-citationGlutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Metadata
- Authors
- Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., Tansella, M., & Barbui, C.
- Affiliations
- University of Verona (IT)
- University of Ioannina (GR)
- University of Oxford (GB)
- University of Cambridge (GB)
- University of Bristol (GB)
- Nagoya City University (JP)
- Keio University (JP)
- Cochrane (GB)
- Corresponding author
- Cipriani, Andrea
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 373
- Issue
- 9665
- Pages
- 746-758
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2149154629
- Cited by
- 1,654
- References
- 135
- Citations by year
- 2026: 30 · 2025: 37 · 2024: 39 · 2023: 45 · 2022: 51 · 2021: 63 · 2020: 101 · 2019: 78 · 2018: 110 · 2017: 106 · 2016: 120 · 2015: 131 · 2014: 115 · 2013: 144 · 2012: 137
- FWCI
- 115.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Funders
- Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- antidepressants, major depressive disorder, second-generation antidepressants, treatment efficacy, treatment acceptability, treatment discontinuation, escitalopram, sertraline, reboxetine, duloxetine, venlafaxine, mirtazapine, paroxetine, fluoxetine, fluvoxamine, bupropion, milnacipran, citalopram
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(09)60046-5
- The paper
- Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., Tansella, M., & Barbui, C. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(09)60046-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.